Auro Laboratories Limited Stock Price Today (NSE: AUROLAB)
Fundamental Score
Auro Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Auro Laboratories Limited share price today is ₹265.00, down 2.50% on NSE/BSE as of 30 March 2026. Auro Laboratories Limited (AUROLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹156.37 (Cr). The 52-week high for AUROLAB share price is ₹317.00 and the 52-week low is ₹159.00. At a P/E ratio of 71.08x, AUROLAB is currently trading above its industry average P/E of 31.77x.
Auro Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Auro Laboratories Limited Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Auro Laboratories Share Price: A Growth Strategist's Perspective
The pharmaceutical industry, historically resistant to economic downturns due to consistent healthcare demand, faces increasing pressure from generic drug pricing and regulatory scrutiny. This analysis examines the current position of Auro Laboratories share price, which currently stands at ₹269.850006, within this dynamic landscape. We are particularly interested in how Auro Laboratories can achieve industry dominance given its financial standing. This analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra.
A key metric to consider is the Price-to-Earnings (PE) ratio. Auro Laboratories' PE of 71.08 suggests that investors are paying a significant premium for each rupee of earnings. This valuation needs to be viewed in context with its peers, such as Mankind Pharma Ltd. While a high PE can indicate growth expectations, it also implies higher risk, especially when contrasted with peers. The management quality of
Mankind Pharma Ltd, for example, influences investor sentiment significantly and can justify a potentially higher or lower PE ratio.Perhaps the most concerning aspect of Auro Laboratories' financial profile is its reported Return on Capital Employed (ROCE) of None%. ROCE is a crucial indicator of how effectively a company utilizes its capital to generate profits. A None% ROCE raises serious questions about the company's operational efficiency and its ability to create shareholder value. This directly impacts the company's "moat" – its competitive advantage. Without a strong ROCE, it's difficult to argue that Auro Laboratories possesses a sustainable, defensible position in the market, particularly when competing with established players in the pharmaceutical sector.
Comparing Auro Laboratories to peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, further highlights the importance of ROCE. Companies with consistently positive and improving ROCE tend to attract more investment and exhibit greater long-term sustainability. Auro Laboratories needs to address the factors contributing to its None% ROCE to improve investor confidence and secure a more competitive position within the pharmaceutical industry. Further investigation into their balance sheet and income statement would be crucial to understanding this further.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Auro Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AUROLAB across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (100.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (185.16%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (52.18%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 71.08x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Elevated Debt Levels (D/E: 1.01)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Limited Institutional Interest (FII+DII: 0.01%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Auro Laboratories Limited Financial Statements
Comprehensive financial data for Auro Laboratories Limited including income statement, balance sheet and cash flow
About AUROLAB (Auro Laboratories Limited)
Auro Laboratories Limited is a dynamic and innovative pharmaceutical company dedicated to the development, manufacture, and distribution of high-quality pharmaceutical products. Co...mmitted to improving global health, Auro Laboratories specializes in crafting a diverse portfolio of active pharmaceutical ingredients (APIs) and advanced drug intermediates. Leveraging cutting-edge research and development capabilities, the company focuses on creating novel formulations and improving existing treatment options. With a robust manufacturing infrastructure, Auro Laboratories adheres to the most stringent international quality standards, ensuring the safety and efficacy of every product. Driven by a team of skilled scientists, engineers, and professionals, Auro Laboratories seeks to address unmet medical needs and make a significant impact on healthcare worldwide. Auro Laboratories Limited is recognized for its strategic approach to pharmaceutical manufacturing, focusing on therapeutic areas with significant patient needs. The company's extensive product range encompasses various therapeutic segments, including treatments for allergies, musculoskeletal disorders, metabolic diseases, and infectious diseases. Auro Laboratories develops and manufactures therapies targeting prevalent conditions such as diabetes, fungal infections, and inflammatory ailments, offering affordable and accessible solutions to healthcare providers and patients alike. Furthermore, the company produces essential supplements, including those addressing iron deficiency and iodine deficiencies, ensuring the availability of vital nutrients in vulnerable populations. Dedicated to expanding its reach and impact, Auro Laboratories continuously invests in new product development and market expansion strategies. Auro Laboratories Limited demonstrates unwavering commitment to sustainable and ethical business practices. The company prioritizes environmental responsibility through implementing eco-friendly manufacturing processes and minimizing its environmental footprint. Auro Laboratories upholds the highest ethical standards in all aspects of its operations, fostering a culture of integrity and transparency. By adhering to rigorous regulatory guidelines and quality control measures, Auro Laboratories ensures that every product meets the highest standards of safety, efficacy, and purity. The company emphasizes building strong relationships with its partners, suppliers, and stakeholders based on trust, collaboration, and mutual respect. Auro Laboratories is dedicated to creating a positive impact on society by providing access to affordable, high-quality medicines and promoting responsible business practices.
Company Details
Key Leadership
AUROLAB Share Price: Frequently Asked Questions
What is the current share price of Auro Laboratories Limited (AUROLAB)?
As of 30 Mar 2026, 12:07 pm IST, Auro Laboratories Limited share price is ₹265.00. The AUROLAB stock has a market capitalisation of ₹156.37 (Cr) on NSE/BSE.
Is AUROLAB share price Overvalued or Undervalued?
AUROLAB share price is currently trading at a P/E ratio of 71.08x, compared to the industry average of 31.77x. Based on this relative valuation, the Auro Laboratories Limited stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of AUROLAB share price?
The 52-week high of AUROLAB share price is ₹317.00 and the 52-week low is ₹159.00. These values are updated daily from NSE/BSE price data.
What factors affect the Auro Laboratories Limited share price?
Key factors influencing AUROLAB share price include quarterly earnings growth (Sales Growth: 185.16%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Auro Laboratories Limited a good stock for long-term investment?
Auro Laboratories Limited shows a 5-year Profit Growth of N/A% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.01 before investing in AUROLAB shares.
How does Auro Laboratories Limited compare with its industry peers?
Auro Laboratories Limited competes with major peers in the Pharmaceuticals. Investors should compare AUROLAB share price P/E of 71.08x and ROE of N/A% against the industry averages to determine competitive standing.
What is the P/E ratio of AUROLAB and what does it mean?
AUROLAB share price has a P/E ratio of 71.08x compared to the industry average of 31.77x. Investors pay ₹71 for every ₹1 of annual earnings.
How is AUROLAB performing according to Bull Run's analysis?
AUROLAB has a Bull Run fundamental score of 24.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does AUROLAB belong to?
AUROLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Auro Laboratories Limited share price.
What is Return on Equity (ROE) and why is it important for AUROLAB?
AUROLAB has an ROE of N/A%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Auro Laboratories Limited generates profits from shareholders capital.
How is AUROLAB debt-to-equity ratio and what does it indicate?
AUROLAB has a debt-to-equity ratio of 1.01, which indicates high leverage that increases financial risk.
What is AUROLAB dividend yield and is it a good dividend stock?
AUROLAB offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Auro Laboratories Limited shares.
How has AUROLAB share price grown over the past 5 years?
AUROLAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in AUROLAB and why does it matter?
Promoters hold 52.18% of AUROLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Auro Laboratories Limited.
What is AUROLAB market capitalisation category?
AUROLAB has a market capitalisation of ₹156 crores, placing it in the Small-cap category.
How volatile is AUROLAB stock?
AUROLAB has a beta of N/A. A beta > 1 suggests the Auro Laboratories Limited stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is AUROLAB operating profit margin trend?
AUROLAB has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is AUROLAB quarterly performance?
Recent quarterly performance shows Auro Laboratories Limited YoY Sales Growth of 185.16% and YoY Profit Growth of 100.00%.
What is the institutional holding pattern in AUROLAB?
AUROLAB has FII holding of 0.00% and DII holding of 0.01%. Significant institutional holding often suggests professional confidence in the Auro Laboratories Limited stock.